Summary
Humana Medicare Advantage updated its Rituximab Products prior authorization policy effective January 1, 2023, with a revision date of June 24, 2026. The policy establishes step-therapy requirements for branded rituximab products (Rituxan, Truxima) across nine covered indications, requiring documented intolerance or contraindication to biosimilars (Ruxience, Riabni) before approval, with exceptions for continuation of prior therapy within 365 days. Key exclusions include high-dose CLL therapies and maintenance therapy duration limits (2 years for CLL and low-grade NHL).
Get alerts when payers change rules like this one
We check Humana and other payers every day and email you when a change matches your specialty and state.
Get Humana alertsPolicy Monitoring is free. No card required.
What to do
Action · 8 steps
01By immediately: Billing and clinical teams must implement prior authorization requirements for all rituximab product claims under Humana Medicare Advantage.
02Update billing system to require prior auth submission for CPT/HCPCS codes J9310, J9311, J9312, J9313 before claim submission.
03For branded products (Rituxan/Truxima - J9310, J9311), configure system to require documentation of intolerance or contraindication to biosimilars (Ruxience/Riabni) UNLESS the claim is a continuation within 365 days of prior approved therapy.
04For CLL and low-grade NHL, add validation rules to flag and deny claims exceeding 2-year maintenance therapy limit or high-dose CLL (>500mg/m²).
05Update provider encounter forms and clinical templates to capture step-therapy status and document prior biosimilar failures.
06Train billing staff on nine covered indications and associated criteria (diagnosis validation, age requirements for WG/MPA, concomitant methotrexate for RA, splenectomy status for ITP).
07Configure system reminders for CD-20 positivity documentation for NHL and Hodgkin's disease claims.
08Establish process to flag continuation-of-therapy requests to bypass step-therapy requirements.
If missed: Failure to obtain required prior authorizations will result in claim denials from Humana Medicare Advantage.
Codes mentioned
J9310J9311J9312J9313
Original notice
Rituximab Products (Revised)
mcp.humana.com · Always check the source before changing claims.
Related changes
See all Humana changes →Rituximab products (Revised)MediumEffective Jan 1, 2026 · MedicaidIntravenous tocilizumab products (Revised)HighEffective Jan 1, 2019 · Medicare AdvantageRituximab Products (New)HighEffective Oct 28, 2026 · MedicaidImjudo (tremelimumab-actl) (Revised)MediumEffective Jan 1, 2025 · MedicaidBrowse every Humana change in the policy list